The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1
note: here is a good write-up by Jessica Rose on the pre-print study.
https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1
note: here is a good write-up by Jessica Rose on the pre-print study.
medRxiv
The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially…
The account of the user that owns this channel has been inactive for the last 5 months. If it remains inactive in the next 29 days, that account will self-destruct and this channel may no longer have an owner.
The account of the user that owns this channel has been inactive for the last 5 months. If it remains inactive in the next 10 days, that account will self-destruct and this channel may no longer have an owner.
https://twitter.com/_Escapekey_/status/1681656412819329024
We have heard nothing of importance from Wuhan lately.
Not since January 10, 2023 to be specific.
That's when this paper was released.
'Innovations in Public Health Surveillance for Emerging Infections'
https://www.annualreviews.org/doi/pdf/10.1146/annurev-publhealth-051920-093141
We have heard nothing of importance from Wuhan lately.
Not since January 10, 2023 to be specific.
That's when this paper was released.
'Innovations in Public Health Surveillance for Emerging Infections'
https://www.annualreviews.org/doi/pdf/10.1146/annurev-publhealth-051920-093141
The owner of this channel has been inactive for the last 11 months. If they remain inactive for the next 28 days, they may lose their account and admin rights in this channel. The contents of the channel will remain accessible for all users.